BR0316386A - Benzoxazin-3-onas e seus derivados como inibidores de p13k - Google Patents

Benzoxazin-3-onas e seus derivados como inibidores de p13k

Info

Publication number
BR0316386A
BR0316386A BR0316386-5A BR0316386A BR0316386A BR 0316386 A BR0316386 A BR 0316386A BR 0316386 A BR0316386 A BR 0316386A BR 0316386 A BR0316386 A BR 0316386A
Authority
BR
Brazil
Prior art keywords
inhibitors
benzoxazin
derivatives
compounds
ones
Prior art date
Application number
BR0316386-5A
Other languages
English (en)
Inventor
Nicole Chantel Barvian
Christine Nylund Kolz
Kimberly Suzanne Para
William Chester Patt
Melean Visnick
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR0316386A publication Critical patent/BR0316386A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"BENZOXAZIN-3-ONAS E SEUS DERIVADOS COMO INIBIDORES DE P13K". A presente invenção refere-se a compostos de fórmula I em que W, Q, E, R¬ 6¬, R¬ 7¬, R¬ 8¬, Y, K, R¬ 9¬, R¬ 10¬, R¬ 12¬, G e a dupla ligação marcada '*' possuindo quaisquer dos valores definidos na descrição, e seus sais farmaceuticamente aceitáveis, que são úteis como agentes no tratamento de doenças e condições, incluindo doenças inflamatórias, doenças cardiovasculares, e cânceres. São também fornecidas composições farmacêuticas constituídas por um ou mais compostos de fórmula I. Os compostos são inibidores de fosfoinositido-3-quinase (PI3-K).
BR0316386-5A 2002-12-06 2003-11-25 Benzoxazin-3-onas e seus derivados como inibidores de p13k BR0316386A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43152802P 2002-12-06 2002-12-06
PCT/IB2003/005451 WO2004052373A1 (en) 2002-12-06 2003-11-25 Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k

Publications (1)

Publication Number Publication Date
BR0316386A true BR0316386A (pt) 2005-09-27

Family

ID=32507748

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316386-5A BR0316386A (pt) 2002-12-06 2003-11-25 Benzoxazin-3-onas e seus derivados como inibidores de p13k

Country Status (8)

Country Link
US (1) US7205295B2 (pt)
EP (1) EP1569653A1 (pt)
JP (1) JP2006510661A (pt)
AU (1) AU2003280188A1 (pt)
BR (1) BR0316386A (pt)
CA (1) CA2508601A1 (pt)
MX (1) MXPA05005585A (pt)
WO (1) WO2004052373A1 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ332762A (en) 1996-07-24 2000-09-29 Warner Lambert Co Isobutylgaba and its derivatives for the treatment of pain
US6455734B1 (en) 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
AU2004261212B2 (en) * 2003-07-28 2011-01-27 Dr. Reddy's Laboratories Ltd. Treatment and prevention of cardiovascular events
WO2005016348A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
EP2543376A1 (en) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
SI3153514T1 (sl) 2004-05-13 2022-02-28 Icos Corporation Kinazolinoni kot zaviralci človeške fosfatidilinozitol 3-kinaze delta
CA2566436C (en) * 2004-05-13 2011-05-10 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US20050255050A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Powder formulations for inhalation, comprising enantiomerically pure beta agonists
US7652051B2 (en) 2004-08-25 2010-01-26 Targegen, Inc. Heterocyclic compounds and methods of use
WO2006024666A1 (en) 2004-09-03 2006-03-09 Applied Research Systems Ars Holding N.V. Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors
CA2579279C (en) 2004-10-07 2013-10-01 Boehringer Ingelheim International Gmbh Tricyclic thiazole derivatives as pi3 kinases
WO2006089106A2 (en) * 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
WO2006095713A1 (ja) * 2005-03-08 2006-09-14 Institute Of Medicinal Molecular Design. Inc. プラスミノゲンアクチベータインヒビター－１阻害剤
TWI381841B (zh) * 2005-03-11 2013-01-11 Zenyaku Kogyo Kk An immunosuppressive agent and an antitumor agent containing a heterocyclic compound as an active ingredient
ES2530991T3 (es) * 2005-08-15 2015-03-09 Boehringer Ingelheim Int Procedimiento para la obtención de betamiméticos
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
PT1951684T (pt) 2005-11-01 2016-10-13 Targegen Inc Inibidores de cinases de tipo biaril-meta-pirimidina
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
US7517995B2 (en) 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
US7601716B2 (en) * 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
ES2289951B1 (es) 2006-07-28 2008-12-16 Universidad De Cadiz Derivados halogenados de benzoxacinonas, con actividad fitotoxica.
EP1953163A1 (en) * 2007-02-01 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Pteridinone derivatives as PI3-kinases inhibitors
FR2919608B1 (fr) * 2007-08-01 2012-10-05 Univ Rennes Derives d'imidazolones,procede de preparation et applications biologiques
US7960377B2 (en) 2008-03-28 2011-06-14 Cara Therapeutics, Inc. Substituted pyridoxazines
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
EP2341052A4 (en) * 2008-09-05 2011-10-12 Shionogi & Co RING-CONDENSED MORPHOLINE DERIVATIVITY WITH PI3K-INHIBITING EFFECT
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
SG10201703911XA (en) 2008-11-13 2017-06-29 Gilead Calistoga Llc Therapies for hematologic malignancies
AU2009325072A1 (en) * 2008-12-12 2011-06-30 Ariad Pharmaceuticals, Inc. Azaindole derivatives as kinase inhibitors
EP2411391A1 (en) 2009-03-24 2012-02-01 Gilead Calistoga LLC Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
KR20120005523A (ko) 2009-04-20 2012-01-16 길리아드 칼리스토가 엘엘씨 고형 종양의 치료 방법
EP2424509A4 (en) * 2009-04-30 2012-11-07 Reddys Lab Ltd Dr MEDICINAL COMBINATION FORMULATIONS WITH DETERMINED DOSAGE
BR112012001325A2 (pt) 2009-07-21 2017-05-02 Gilead Calistoga Llc tratamento de distúrbios do fígado com inibidaores de pi3k
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
PL2794600T3 (pl) 2011-12-22 2018-06-29 Novartis Ag Pochodne 2,3-dihydro-benzo[1,4]oksazyny i powiązane związki jako inhibitory kinazy fosfoinozytydu-3 (PI3K) do leczenia np. reumatoidalnego zapalenia stawów
IN2014DN07105A (pt) 2012-03-05 2015-04-24 Gilead Calistoga Llc
EP3083623A1 (en) 2013-12-20 2016-10-26 Gilead Calistoga LLC Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
NZ736970A (en) 2013-12-20 2018-11-30 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
CN106459005A (zh) 2014-06-13 2017-02-22 吉利德科学公司 磷脂酰肌醇3‑激酶抑制剂
EP3694511A1 (en) 2017-10-13 2020-08-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination treatment of pancreatic cancer
US12000833B2 (en) 2017-11-23 2024-06-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Marker for predicting the sensitivity to PI3K inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63230689A (ja) * 1987-03-18 1988-09-27 Tanabe Seiyaku Co Ltd ベンゾオキサジン誘導体
US5703075A (en) * 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
US6355664B1 (en) * 1997-03-03 2002-03-12 Boehringer Ingelheim Pharmaceuticals, Inc. Phenylpyrrolidines, phenylimidazolidines, 3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease
AU5311800A (en) 1999-06-10 2001-01-02 Warner-Lambert Company Rhodanine derivatives for use in a method of inhibiting amyloid protein aggregation and imaging amyloid deposits
CA2370316A1 (en) 1999-06-10 2000-12-21 Warner-Lambert Company Rhodanine derivatives and their use in inhibiting and imaging amyloids
ATE551325T1 (de) * 2000-01-24 2012-04-15 Astrazeneca Ab Therapeutische morpholino-substituierte verbindungen
EP2223922B1 (en) 2000-04-25 2016-03-02 ICOS Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
EP1277738B1 (en) 2000-04-27 2011-03-30 Astellas Pharma Inc. Condensed heteroaryl derivatives
RS115904A (en) * 2002-07-10 2006-12-15 Applied Research Systems Ars Holding N.V. Azolidinone-vinyl fused benzene derivatives
US20040092561A1 (en) * 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives

Also Published As

Publication number Publication date
MXPA05005585A (es) 2005-07-27
US20040121996A1 (en) 2004-06-24
WO2004052373A1 (en) 2004-06-24
US7205295B2 (en) 2007-04-17
EP1569653A1 (en) 2005-09-07
JP2006510661A (ja) 2006-03-30
AU2003280188A1 (en) 2004-06-30
CA2508601A1 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
BR0316386A (pt) Benzoxazin-3-onas e seus derivados como inibidores de p13k
BR0317572A (pt) Benzoxazinas e seus derivados como inibidores de pi3ks
BR0316081A (pt) Derivados de 2-piridona como inibidores de elastase de neutrófilo
BRPI0512938A (pt) derivados da quinazolinediona como inibidores parp
BRPI0513184A (pt) derivados de 2-carbamida-4-feniltiazol, preparação dos mesmos e aplicação dos mesmos em terapia
BRPI0411017A (pt) indóis 3-substituìdos e derivados dos mesmos como agentes terapêuticos
BRPI0515477A (pt) derivados heterocìclicos bicìclicos e o uso dos mesmos como inibidores de estaroil-coa-desaturase (scd)
BRPI0517463A (pt) inibidores da protease do vìrus da hepatite c, composições e tratamentos usando os mesmos
BRPI0515594A (pt) inibidores da interação entre mdm2 e p53
BR0206496A (pt) Diaminotiazóis
NO20072689L (no) Tetrasykliske indolderivater som antivirale midler
BRPI0507041A (pt) composto derivados de sulfonamida para o tratamento de doenças seus usos, processo para a preparação dos compostos e combinação de compostos
BRPI0513379A (pt) derivados de sulfonamida
BRPI0512790A (pt) derivados de 2-alquil quinazolinona substituìdos como inibidores de parp
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
BRPI0417458A (pt) compostos inibidores de dpp-iv, sais faramaceuticamente aceitáveis e pró-fármacos do mesmo, seus processos de preparação, composição farmacêutica compreendendo os mesmos e uso dos referidos compostos na fabricação de medicamento
NO20085212L (no) Nye pyridinanaloger
BRPI0410660A (pt) derivados de 2-amino-piridina como agonistas de adrenoreceptor ß2
NO20073101L (no) Nye pyridinforbindelser
BRPI0511722A (pt) 3-amino-1-arilpropilindóis como inibidores da recaptação de monoamina
BRPI0414011A (pt) naftalencarboxamidas e seus derivados úteis como novos agentes antiangiogênicos
BRPI0411092A (pt) benzo[b]tiofenos substituìdos com 3-arilsulfanila e com 3-heteroarilsulfanila como agentes terapêuticos
BR0307574A (pt) Derivados de nicotinamida úteis como inibidores de pde4
BR0212069A (pt) Agentes antidiabéticos orais
BRPI0414948A (pt) derivados de pirazolo-e-imidazo pirimidina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.